Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine in Cameroon
NCT03719066Phase 2Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Oct 2018
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cholera vaccine (inactivated, oral) in cholera (3 arms), sponsored by Johns Hopkins Bloomberg School of Public Health. Primary endpoint: Vibriocidal geometric mean titer. Started Oct 2018; status: completed.
02
Drugs
cholera vaccine (inactivated, oral)
03
Conditions
cholera
Beyond the preview
Go deeper on NCT03719066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719066.